United Kingdom G-protein coupled receptors (GPCRs) Market Insight
The United Kingdom Fragment-Based Drug Discovery Market is growing at an 11.98% CAGR, driven by rising demand for efficient drug development, increasing adoption of structure-based design, and strong research support from organizations such as the Medical Research Council, with innovations in screening technologies improving lead optimization and success rates.
United Kingdom G-protein coupled receptors (GPCRs) Market Insights Forecasts to 2035
- The United Kingdom G-protein coupled receptors (GPCRs) Market Size Was Estimated at USD 204.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.15% from 2025 to 2035
- The United Kingdom G-protein coupled receptors (GPCRs) Market Size is Expected to Reach USD 408.3 Million by 2035
Notable Insights for United Kingdom G-protein coupled receptors (GPCRs) Market
- By product type, small molecule drugs dominated, accounting for approximately 65–70% share in 2024, driven by established efficacy and broad therapeutic applications.
- By application, oncology and cardiovascular diseases held approximately 55–60% share, due to high GPCR involvement in disease signaling pathways.
- Approximately 30–35% of drug targets in the UK pharmaceutical pipeline involve GPCRs, reflecting their critical role in modern drug discovery.
- Around 60–70% of pharmaceutical companies focus on GPCR-based research due to their high success rate in targeted therapies and biologics development.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom G-protein coupled receptors (GPCRs) Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom G-protein coupled receptors (GPCRs) Market
- GlaxoSmithKline
- AstraZeneca
- Novartis
- Roche
- Pfizer
- Johnson & Johnson
- Merck & Co.
- Thermo Fisher Scientific
- Others
Recent Developments:
- In January 2025: Isogenica and Cube Biotech partnered to combine synthetic VHH libraries with GPCR stabilization technology, accelerating antibody discovery for challenging GPCR targets.
- In November 2024: Nxera Pharma partnered with Antiverse to develop GPCR-targeted antibody therapeutics using generative AI, accelerating drug discovery through combined structural biology and AI-driven platforms.
Market Segmentation:
United Kingdom G-protein coupled receptors (GPCRs) Market, By Product Type
- Small Molecules
- Biologics
- Peptides
- Others
United Kingdom G-protein coupled receptors (GPCRs) Market, By Application
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Others
United Kingdom G-protein coupled receptors (GPCRs) Market, By End User
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Contract Research Organizations (CROs)
United Kingdom G-protein coupled receptors (GPCRs) Market, By Distribution Channel
- Direct Sales
- Online Platforms
- Distributors
Expert Views:
The UK GPCRs Market is expected to witness robust growth due to increasing reliance on targeted therapies and precision medicine. Experts highlight that GPCRs will remain central to drug discovery, supported by AI integration and structural biology advancements. Continued innovation in ligand design, receptor modelling, and biologics is anticipated to expand therapeutic applications and accelerate market growth through 2035.